Journal of Arrhythmia最新文献

{"title":"Dementia risk reduction between DOACs and VKAs in AF: A systematic review and meta-analysis","authors":"Anthipa Chokesuwattanaskul MD,&nbsp;Narut Prasitlumkum MD,&nbsp;Ryan Cooley MD,&nbsp;T. Jared Bunch MD,&nbsp;Ronpichai Chokesuwattanaskul MD,&nbsp;Leenhapong Navaravong MD, FACC, FHRS","doi":"10.1002/joa3.13142","DOIUrl":"https://doi.org/10.1002/joa3.13142","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Direct oral anticoagulants (DOACs) become the recommended treatment over vitamin K antagonists (VKA) in patients with non-valvular atrial fibrillation (AF). However, their effectiveness in reducing cognitive impairment and dementia compared to VKA remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic literature search was conducted on Ovid MEDLINE, EMBASE, and Cochrane Database. Randomized controlled trials, cohort, or case–control study that assessed incident dementia between AF patients who received DOAC compared to VKA were selected. Relevant study characteristics and the number of incident dementia diagnosis or hazard ratios (HRs) for incident dementia and each dementia subtypes were extracted. Random-effects model was used to perform meta-analysis. Standardized mean differences (SMDs) were used to estimate effect sizes for continuous data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twelve cohort studies comprising 1 451 069 individuals were included. The incidence of dementia was lower in AF patients prescribed DOACs compared to VKA (HR 0.88, 95% CI 0.83–0.93, <i>I</i>\u0000 ² = 61.2%). A lower incident dementia in DOACs group relative to VKA was significantly observed in those less than 75 years of age (&lt; 65 years, HR 0.83 (95% CI 0.72–0.97, <i>I</i>\u0000 ² = 0%); 65–74 years, HR 0.86 (95% CI 0.81–0.92, <i>I</i>\u0000 ² = 55.4%); and ≥ 75 years, HR 1.07 (95% CI 0.74–1.55, <i>I</i>\u0000 ² = 92.5%)) and for the subgroup of patients with vascular dementia (HR 0.91, 95% CI 0.824–0.997, <i>I</i>\u0000 ² = 0%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This meta-analysis reveals a reduction in incidence of dementia in AF patients prescribed DOACs compared to VKA, particularly in those less than 75 years old and in the vascular dementia subtype.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/joa3.13142","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142435501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electro-anatomically confirmed sites of origin of ventricular tachycardia and premature ventricular contractions and occurrence of R wave in lead aVR: A proof of concept study","authors":"Zainul Abedin MD,&nbsp;Seth Smith BS,&nbsp;Lakshmi Kattamuri MD,&nbsp;Amy Melendez CEPS,&nbsp;Moeen Abedin MD","doi":"10.1002/joa3.13147","DOIUrl":"https://doi.org/10.1002/joa3.13147","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The R wave in lead aVR, during the wide QRS complex tachycardia, is commonly observed in a ventricular tachycardia (VT) arising from certain locations in the ventricles.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This was a retrospective and a proof of concept study to correlate the sites of origin of VT and premature ventricular contractions (PVCs) with the occurrence of R wave in lead aVR.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with VT or high density of PVCs were included. Surface and intracardiac electrograms were recorded during the arrhythmia. VTs and PVCs arising from the inferior, inferolateral, or apical region of the ventricles were grouped into Zone 2. Those arising from the other areas of the ventricles were grouped into Zone 1.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Sixty-four patients were included in the study. The mean age was 57 years. There were 47 males. Among 64 patients with VT or PVCs, 28 patients had an R wave in aVR (43.7%), In 26 of 28 patients with an R wave in aVR, the site of origin of the arrhythmia was in Zone 2. The R wave in aVR was absent in 36 patients, 34 of whom had the origin of arrhythmia focus in Zone 1. The presence of an R wave in aVR correctly identified Zone 2 as a site of origin of the arrhythmia with high sensitivity (93%) and specificity (94%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The presence of an R wave in aVR during wide QRS complex tachycardia or PVC is a valuable observation for identifying the site of origin of the arrhythmia and hence in distinguishing supraventricular tachycardia with aberrancy from VT.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/joa3.13147","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142435112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Slow left atrial conduction velocity in the anterior wall calculated by electroanatomic mapping predicts atrial fibrillation recurrence after catheter ablation—Systematic review and meta-analysis","authors":"Antonia Anna Lukito MD, PhD,&nbsp;Wilson Matthew Raffaello MD,&nbsp;Raymond Pranata MD","doi":"10.1002/joa3.13146","DOIUrl":"https://doi.org/10.1002/joa3.13146","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This study aimed to investigate and perform diagnostic test meta-analysis on whether slow left atrial conduction velocity (LACV) in the anterior wall calculated by electroanatomic mapping predicts atrial fibrillation (AF) recurrence after catheter ablation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Extensive literature search was performed on PubMed, SCOPUS, and EuropePMC up to June 5, 2024. The exposure group included AF patients with slow LACV in the anterior wall, while the control group included AF patients without slow LACV in the anterior wall. Slow LACV in the anterior wall was defined as LACV below study-specific cut-off points in m/s, measured by invasive electroanatomic mapping. The primary outcome of this study was AF recurrence, defined as AF/Atrial Flutter/Atrial Tachyarrhythmias lasting over 30 s at least 3 months after the blanking period postablation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>This systematic review and meta-analysis included seven studies, involving a sample size of 1428 patients with mean follow-up duration were 13 months. Patients with AF recurrence has slower LACV in the anterior wall (mean difference − 0.16 m/s [−0.18, −0.15], <i>p</i> &lt; .001). Slow LACV in the anterior wall defined as LACV below 0.70–0.88 m/s was associated with increased AF (adjusted OR 3.41 [1.55, 7.50], <i>p</i> = .002). Slow LACV in the anterior wall has an AUROC of 0.80 [0.76–0.83], sensitivity of 70% [52, 84], specificity of 76% [67, 83], positive likelihood ratio of 2.9 [2.3, 3.6], negative likelihood ratio of 0.39 [0.25, 0.63] for predicting AF recurrence postablation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Slow LACV in the anterior wall was associated with AF recurrence after catheter ablation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/joa3.13146","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142435172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Japanese Catheter Ablation Registry (J-AB): Annual report in 2022","authors":"Kengo Kusano MD, PhD,&nbsp;Koichi Inoue MD, PhD,&nbsp;Koshiro Kanaoka MD, PhD,&nbsp;Koji Miyamoto MD, PhD,&nbsp;Yasuo Okumura MD, PhD,&nbsp;Yu-ki Iwasaki MD, PhD,&nbsp;Kazuhiro Satomi MD, PhD,&nbsp;Seiji Takatsuki MD, PhD,&nbsp;Kohki Nakamura MD, PhD,&nbsp;Yoshitaka Iwanaga MD, PhD,&nbsp;Teiichi Yamane MD, PhD,&nbsp;Wataru Shimizu MD, PhD,&nbsp;J-AB registry investigators","doi":"10.1002/joa3.13141","DOIUrl":"https://doi.org/10.1002/joa3.13141","url":null,"abstract":"<p>The Japanese Catheter Ablation (J-AB) registry, started in August 2017, is a voluntary, nationwide, multicenter, prospective, observational registry, performed by the Japanese Heart Rhythm Society (JHRS) in collaboration with the National Cerebral and Cardiovascular Center. From January 2022, the data registration system was changed from Research Electronic Data Capture (REDCap) system to Fountayn system. The purpose of this registry was to collect the details of target arrhythmias, the ablation procedures, including the type of target arrhythmias, outcomes, and acute complications in the real-world settings. During the year of 2022, we have collected a total of 90,042 procedures (mean age of 66.7 years and 65.9% male) from 614 participant hospitals. Detailed data were shown in Figures and Tables.</p>","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/joa3.13141","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142435171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Real-world” performance of the Confirm Rx™ SharpSense AF detection algorithm: UK Confirm Rx study","authors":"Andre Briosa e Gala MD,&nbsp;Michael T. B. Pope BM, BSc,&nbsp;Milena Leo MD, PhD,&nbsp;Alexander J. Sharp MBBS, BSc,&nbsp;Abhirup Banerjee PhD,&nbsp;Duncan Field MD,&nbsp;Honey Thomas MD,&nbsp;Richard Balasubramaniam Mb, ChB, PhD,&nbsp;Ross Hunter PhD,&nbsp;Roy S. Gardner MD,&nbsp;David Wilson DM,&nbsp;Mark M. Gallagher MD,&nbsp;Julian Ormerod PhD,&nbsp;John Paisey MD,&nbsp;Nick Curzen PhD,&nbsp;Timothy R. Betts MD","doi":"10.1002/joa3.13124","DOIUrl":"https://doi.org/10.1002/joa3.13124","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>The novel Confirm Rx™ implantable cardiac monitor (ICM) with SharpSense™ technology incorporates a new P-wave discriminator designed to improve AF detection. This study aimed to evaluate the diagnostic performance of the Confirm Rx™ ICM in detecting AF episodes of varying durations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a multicenter retrospective analysis of consecutive patients implanted with a Confirm Rx™ ICM (v1.2) across nine UK hospitals, all with documented AF lasting at least 6 min. Electrocardiograms (ECGs) were manually adjudicated by cardiologists. To account for intra- and inter-reviewer variability, a random sample of 10% of ECGs underwent additional review. Disagreements were resolved by a third reviewer. Diagnostic performance was determined by calculating the gross and patient-averaged positive predictive value (PPV) for AF episodes of different duration. The source of false positive (FP) detection was also categorized.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall, 16,230 individual ECGs from 232 patients were included. The median AF episode duration was 14 min. R-wave amplitude remained stable during follow-up (0.52 ± 0.27 mV [initial] vs. 0.54 ± 0.29 mV [end of follow-up], <i>p</i> = .10). The gross and patient-averaged PPV were 75.0% and 67.0%, respectively. Diagnostic performance (gross) increased with progressively longer AF episodes: 88.0% for ≥1 h, 97.3% for 6 h, and 100% for 24 h. The main source of FP during tachycardia was T-wave oversensing (54.2%), while in non-tachycardic episodes it was predominantly ectopy (71.2%). The AF burden precision was excellent (93.3%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The Confirm Rx™ ICM diagnostic performance was modest for all AF episodes (75%), with accuracy increasing for longer AF episodes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/joa3.13124","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142435245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The incidence and risk factors of atrial high-rate episodes in patients with a dual-chamber pacemaker","authors":"Son Khac Le Nguyen MD,&nbsp;Dung Ngoc Kieu MD,&nbsp;Phuong Le Uyen Tran MD,&nbsp;Chuong Khac Thien Nguyen MD,&nbsp;Toan Quang Dang MD,&nbsp;Chieu Van Ly MD,&nbsp;Sy Van Hoang MD, PhD,&nbsp;Thuc Tri Nguyen MD, PhD","doi":"10.1002/joa3.13143","DOIUrl":"https://doi.org/10.1002/joa3.13143","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objectives</h3>\u0000 \u0000 <p>Cardiovascular implantable electronic devices can detect atrial high-rate episodes (AHREs). However, the predictors of clinically relevant AHREs have not been well identified.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This prospective study included 145 patients (median age 64.5 ± 16.4 years, 53.1% females) without atrial fibrillation (AF) from December 2020 to January 2022. AHREs were defined as a programmed atrial detection rate &gt;190 beats per minute. Cox regression analysis was used to identify the risk factors of AHREs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>During 6 months of follow-up, AHREs occurred in 30.3% of patients. Multivariable Cox regression analysis showed factors related to development of AHREs including using anti-arrhythmic drugs (AAD) before implantation (Hazard ratio (HR) 7.71; 95% confidence interval [95% CI], 2.58–23.02, <i>p</i> &lt; .001), history of paroxysmal supraventricular tachycardia (PSVT; HR 2.45; [95% CI], 1.18–5.09, <i>p</i> = .016), the percentage of premature atrial contraction (PAC) on 24-h Holter electrocardiogram (ECG) monitoring (HR 1.008; [95% CI], 1.003–1.014, <i>p</i> = .003), and left ventricular global longitudinal strain (GLS-LV; HR 0.92;[95% CI], 0.84–0.99, <i>p</i> = .049).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study showed that a history of PSVT and using AAD, the percentage of PAC on 24-h Holter ECG monitoring, and GLS-LV were the independent predictors of new-onset AHREs.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/joa3.13143","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142435038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial to “Atypical atrial resetting with ventricular extrastimulus during tachycardia: What is the mechanism?”","authors":"Tatsuya Hayashi MD, PhD,&nbsp;Hideo Fujita MD, PhD","doi":"10.1002/joa3.13144","DOIUrl":"https://doi.org/10.1002/joa3.13144","url":null,"abstract":"&lt;p&gt;Editorial to “Atypical atrial resetting with ventricular extrastimulus during tachycardia: What is the mechanism?”&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;\u0000 &lt;/p&gt;&lt;p&gt;The use of catheter ablation to treat tachyarrhythmias initially involved targeting the atrioventricular node (AV node). Over time, as specific arrhythmic circuits have been discovered, it has become feasible to perform ablations at safer and more efficient locations beyond the AV node. This technique is now utilized to address a wide range of arrhythmias. Supraventricular tachycardia (SVT) is generally classified into atrioventricular nodal reentrant tachycardia (AVNRT), orthodromic reciprocating tachycardia (ORT), and atrial tachycardia (AT), all of which have been successfully treated with catheter ablation, and SVT treatment is now largely established.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; However, despite these successes already achieved, recent electrophysiological study (EPS) advancements have uncovered new insights into SVT, suggesting that the success of catheter ablation and understanding the true mechanism of the tachycardia circuit are different things. This is exemplified by the recent “re-discovery” of the nodoventricular (NVP) and nodofascicular pathways (NFP), which can often exist as a bystander pathway in successful AVNRT cases with slow pathway ablation.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; These evolving insights have added complexity to SVT differentiation, necessitating a broader differential diagnosis approach during treatment. We electrophysiologists have witnessed the maturation of diagnosis and treatment of SVT over decades, and now we realize that it is further developing into something like “SVT -Season 2.” In this study, Kobari et al. reported a complex case of supraventricular tachycardia that required detailed analysis for diagnosis and was successfully ablated.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; In this case, the first EPS findings suggested that the mechanism of SVT was ORT. For example, the initial atrial (A) and ventricular (V) activation at the time of overdrive ventricular stimulation cessation was a V-A-V sequence, and the postpacing interval at the stimulation site minus the tachycardia cycle length was 67 ms. The treatment approach for “pre-modern” SVT may involve directly ablating the earliest atrial excited site without further detailed examination. However, this approach is insufficient in the current “SVT-season 2,” and a deeper understanding is essential. It is crucial to distinguish whether the diagnosis is ORT via a slow conduction accessory pathway (AP) or through an NVP. In ORT involving a typical or slow conduction AP, the atrium is an essential part of the tachycardia circuit, whereas in ORT using an NVP, the atrium is not involved in the tachycardia circuit. Based on this background, this paper determined that the atrium is not a crucial part of the tachycardia circuit as the AH duration during tachycardia is significantly different from the AH duration during atrial sti","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/joa3.13144","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142435051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distribution of anti-factor Xa activity in patients with nonvalvular atrial fibrillation receiving 15 mg dose of edoxaban","authors":"Shotaro Hiramatsu MD,&nbsp;Hiroyuki Osanai MD,&nbsp;Yuichiro Sakai MD,&nbsp;Yoshiki Sogo MD,&nbsp;Yuki Tanaka MD,&nbsp;Hikari Matsumoto MD,&nbsp;Shun Miyamoto MD,&nbsp;Kensuke Tagahara MD,&nbsp;Kenji Arai MD,&nbsp;Takashi Watanabe MD,&nbsp;Yusuke Sakamoto MD,&nbsp;Teruhiro Sakaguchi MD, PhD,&nbsp;Shioh Oguchi MD,&nbsp;Takahiro Kanbara MD, PhD,&nbsp;Yoshihito Nakashima MD,&nbsp;Hiroshi Asano MD,&nbsp;Masayoshi Ajioka MD","doi":"10.1002/joa3.13139","DOIUrl":"https://doi.org/10.1002/joa3.13139","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The distribution of anti-factor Xa activity (AXA) in patients with nonvalvular atrial fibrillation (NVAF) taking edoxaban 15 mg has not been fully elucidated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>The trough and peak AXA were measured in 19 NVAF patients taking edoxaban 15 mg. We compared these results with those in patients taking edoxaban 30 mg. The peak AXA differed significantly between the 15 mg and the 30 mg groups (0.74 ± 0.40 IU/mL vs. 1.25 ± 0.48 IU/mL, respectively; <i>p</i> &lt; 0.0001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Peak but trough AXA in the patients receiving edoxaban 15 mg were significantly lower than those in patients receiving edoxaban 30 mg.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/joa3.13139","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142435917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decremental conduction property in the slow conduction zone of adenosine-sensitive atrial tachycardia","authors":"Takahiko Kinjo MD, PhD,&nbsp;Masaomi Kimura MD, PhD,&nbsp;Noriyoshi Kaname MD, PhD,&nbsp;Daisuke Horiuchi MD, PhD,&nbsp;Hirofumi Tomita MD, PhD","doi":"10.1002/joa3.13140","DOIUrl":"https://doi.org/10.1002/joa3.13140","url":null,"abstract":"<p>In the case of adenosine-sensitive atrial tachycardia originating near the atrioventricular (AV) node, overdrive pacing from the anterior right atrium showed constant and progressive fusion, indicating that the pacing site is proximal to slow conduction. Shortening the pacing cycle length prolonged conduction times to the orthodromic capture sites; they remained unchanged at the antidromic capture sites. Limited decremental conduction property in the slow conduction zone supports the hypothesis that AV node-like tissue remnants along the AV annulus are involved.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </p>","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/joa3.13140","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142435918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of atrial fibrillation based on tertiary hospital survey in Indonesia: A smartphone-based diagnosis","authors":"Yoga Yuniadi MD PhD,&nbsp;Alice I. Supit MD,&nbsp;Dicky A. Hanafy MD PhD,&nbsp;Sunu B. Raharjo MD PhD,&nbsp;Dony Y. Hermanto MD,&nbsp;Faris Basalamah MD PhD,&nbsp;Benny Hartono MD,&nbsp;Reynold Agustinus MD,&nbsp;Agung F. Chandranegara MD,&nbsp;Chaerul Ahmad MD PhD,&nbsp;Mohammad Iqbal MD PhD,&nbsp;Alexander E. Tondas MD PhD,&nbsp;Hauda El-Rasyid MD,&nbsp;Haryadi Haryadi MD,&nbsp;Antonia A. Lukito MD PhD,&nbsp;Daniel Tanubudi MD,&nbsp;Ignatius Yansen MD,&nbsp;Erika Maharani MD,&nbsp;Rerdin Julario MD,&nbsp;Ardian Rizal MD,&nbsp;Putra S. Antara MD,&nbsp;Muzakkir Amir MD PhD","doi":"10.1002/joa3.13137","DOIUrl":"https://doi.org/10.1002/joa3.13137","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Atrial fibrillation (AF) is one of the most common arrhythmic disorders worldwide. This study aims to describe the prevalence of AF in various cities in Indonesia using single-lead hand held electrocardiography linked to a smartphone-based application.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This is a cross-sectional epidemiological study conducted at tertiary hospital of major cities in Indonesia, between January 2018 and July 2019. The AliveCor Kardia™ Mobile system device was used as a screening tool for AF and confirmed its finding with clinical diagnoses made by cardiologists.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 9773 subjects were enrolled in this study. The prevalence of AF reported by the device and cardiologist was 3.2% and 3.5%, respectively. AF prevalences are equal in men than women. The majority of subjects (56%) are having low risk for stroke or systemic thromboembolism. Prevalence of risk factors such as heart failure, hypertension, diabetes, and history of stroke among AF patients were 50%, 22.9%, 31.9%, 13.5%, and 5.8%, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The prevalence of AF at referral hospitals visitors based on smartphone diagnosis in Indonesia is 3.2%.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/joa3.13137","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142435767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}